Everest Organics has successfully completed USFDA inspection at its flagship API manufacturing facility in Hyderabad. The company has vision to enter into very niche areas of high margin API products as well as development of new products through its R & D, thereby increasing both top line as well as substantial improvement in bottom line in forthcoming years.
Everest Organics is engaged in the business of bulk drugs and active pharmaceutical ingredients (APIs). It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen and Benzimadizole.
